P4O2 ILD Extension

Recruiting Observational Study
Interstitial Lung Disease Pulmonary Fibrosis Interstitial Lung Fibrosis IPF Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis Idiopathic Familial Chronic Hypersensitivity Pneumonitis Unclassifiable ILD Idiopathic NSIP CTD-ILD
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 80
Sex
Any
Study type
Observational
Participants needed
450 (estimated)
Sponsor
Amsterdam UMC, location VUmc · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The goal of this observational study is to identify early biomarkers that can predict the development of progressive pulmonary fibrosis (PPF) in participants with interstitial lung diseases (ILDs). The participant population includes adults diagnosed with idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), other fibrotic ILDs, and interstitial lung abnormalities (ILA). The mai…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Diagnosis of (1) idiopathic pulmonary fibrosis (IPF), familial pulmonary fibrosis (FPF), (2) other fibrotic ILDs (fILD), including fibrotic hypersensitivity pneumonitis (fHP), idiopathic non-specific interstitial pneumonia (iNSIP), connective tissue disease (CTD)-ILD, and uncl…
Contacts

Jan Willem Duitman, PhD

0205668753

j.w.duitman@amsterdamumc.nl

CONTACT

Iris Simons, MD

0205668753

i.simons@amsterdamumc.nl

CONTACT